Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Amgen and others to inform advisory group

Amgen and others to inform advisory group

7th May 2008

Cancer specialist Amgen has been invited to take part in a closed meeting of the Scientific Advisory Group on Oncology (SAG-O) to examine the results of clinical trials and other data.

The meeting will concentrate on studies begun since July last year and other information relating to the impact of erythropoiesis-stimulating agent on tumour progression and survival of cancer patients.

This includes previously published interim results from the Prepare study in neoadjuvant breast cancer therapy, plus follow-up data from the Gynaecologic Oncology Group cervical cancer study which was published in Gynaecologic Oncology and also the Journal of the American Medical Association in February.

Other marketing authorisation holders will also take part in the discussion on May 15th.

Founded in 1980, Amgen also specialises in therapies to combat kidney disease, rheumatoid arthritis and other serious illnesses.

Last year company revenue totalled $14.8 billion (£7.5 billion), $14.3 billion of which was through product sales.

It invested $3.1 billion in to research and development.

We currently have 9 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.